Amgen (NASDAQ:AMGN – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy ...
AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...
Quantbot Technologies LP boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 219.5% during the fourth ...
In fact, Remicade took 28 months to reach the 80% target, and after 12 months Enbrel had only reached 50% of eligible patients. That changed with the next two biosimilars to come online ...
The marketed biosimilars are versions of big-selling brands, including Amgen's Enbrel (etanercept), AbbVie's Humira (adalimumab), Johnson & Johnson's Remicade (infliximab) – all TNF inhibitors ...
The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...
Although the Dow Jones EuroStoxx 50 was only introduced in February 1998, its prices were calculated retroactively back to the year 1986. (read more) The EuroStoxx 50 consists of the shares of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback